Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2021-09-24 19:57:50 UTC |
---|
Update Date | 2021-09-24 19:57:50 UTC |
---|
HMDB ID | HMDB0304850 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Avapritinib |
---|
Description | Avapritinib, also known as BLU-285 or ayvakit, belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. Based on a literature review a significant number of articles have been published on Avapritinib. |
---|
Structure | CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1 InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(1S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-F)(1,2,4)triazin-4-yl)-1-piperazinyl)-5-pyrimidinyl)ethanamine | HMDB | BLU-285 | HMDB | Ayvakit | HMDB |
|
---|
Chemical Formula | C26H27FN10 |
---|
Average Molecular Weight | 498.57 |
---|
Monoisotopic Molecular Weight | 498.240419072 |
---|
IUPAC Name | (1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine |
---|
Traditional Name | (1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethanamine |
---|
CAS Registry Number | Not Available |
---|
SMILES | CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1 |
---|
InChI Identifier | InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1 |
---|
InChI Key | DWYRIWUZIJHQKQ-SANMLTNESA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazinanes |
---|
Sub Class | Piperazines |
---|
Direct Parent | N-arylpiperazines |
---|
Alternative Parents | |
---|
Substituents | - N-arylpiperazine
- Pyrrolo[2,1-f][1,2,4]triazine
- Dialkylarylamine
- Aralkylamine
- Halobenzene
- Fluorobenzene
- Aminopyrimidine
- 1,2,4-triazine
- Imidolactam
- Benzenoid
- Triazine
- Substituted pyrrole
- Pyrimidine
- Monocyclic benzene moiety
- Aryl halide
- Aryl fluoride
- Heteroaromatic compound
- Pyrrole
- Pyrazole
- Azole
- Azacycle
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Primary amine
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Primary aliphatic amine
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Avapritinib,1TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 4964.1 | Semi standard non polar | 33892256 | Avapritinib,1TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 4497.6 | Standard non polar | 33892256 | Avapritinib,1TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 6154.4 | Standard polar | 33892256 | Avapritinib,2TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C)[Si](C)(C)C)C=N5)CC4)C3=C2)C=N1 | 4863.1 | Semi standard non polar | 33892256 | Avapritinib,2TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C)[Si](C)(C)C)C=N5)CC4)C3=C2)C=N1 | 4561.9 | Standard non polar | 33892256 | Avapritinib,2TMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C)[Si](C)(C)C)C=N5)CC4)C3=C2)C=N1 | 5977.1 | Standard polar | 33892256 | Avapritinib,1TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C(C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 5167.0 | Semi standard non polar | 33892256 | Avapritinib,1TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C(C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 4688.1 | Standard non polar | 33892256 | Avapritinib,1TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](C)(N[Si](C)(C)C(C)(C)C)C6=CC=C(F)C=C6)C=N5)CC4)C3=C2)C=N1 | 6115.6 | Standard polar | 33892256 | Avapritinib,2TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=N5)CC4)C3=C2)C=N1 | 5197.1 | Semi standard non polar | 33892256 | Avapritinib,2TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=N5)CC4)C3=C2)C=N1 | 4937.0 | Standard non polar | 33892256 | Avapritinib,2TBDMS,isomer #1 | CN1C=C(C2=CN3N=CN=C(N4CCN(C5=NC=C([C@](C)(C6=CC=C(F)C=C6)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=N5)CC4)C3=C2)C=N1 | 5890.7 | Standard polar | 33892256 |
|
---|